Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pimecrolimus. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A known ✓ | P62942 | 18/20 | 0.90 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | FKBP4 | Q02790 | 2/20 | 0.90 |
| ▸ | MEN1 | O00255 | 1/20 | 0.90 |
| ▸ | LMNA | P02545 | 1/20 | 0.90 |
| ▸ | MAPT | P10636 | 1/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.90 |
| ▸ | THRB | P10828 | 1/20 | 0.90 |
| ▸ | PPP3CA | Q08209 | 2/20 | 0.79 |
| ▸ | MLNR | O43193 | 1/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.79 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.79 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.79 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.79 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.79 |
| ▸ | HTR2A | P28223 | 1/20 | 0.79 |
| ▸ | HTR2B | P41595 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimecrolimus SCHEMBL3854625 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL8194907 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL4651515 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL438880 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL117937 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL436549 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL9947518 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL4456276 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL15277958 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL10241642 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 19176 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636319-B2 | Pharmaceutical composition for preventing or treating atopic disease containing Akkermansia muciniphila strain | ENTEROBIOME INC. (KR) | 2026-05-26 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137842-A1 | DRUG COATED DEVICES AND METHODS FOR THE TREATMENT OF EYE DISEASE | J.D. FRANCO & CO., LLC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260132184-A1 | CD33 TARGETED IMMUNOTHERAPIES | REGENERON PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-12622934-B2 | Pharmaceutical composition for preventing or treating atopic disease containing Faecalibacterium prausnitzii strain | ENTEROBIOME INC. (KR) | 2026-05-12 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-20260108463-A1 | NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2026-04-23 | — | — | US | claimed |
| EP-4727608-A1 | A DRUG-ELUTING STENT COMPRISING A BIOCOMPATIBLE THERMOPLASTIC POLYMER LINING AND A DRUG-CONTAINING COATING | Scitech Medical Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4724051-A1 | LIPID-POLYMER HYBRID NANOPARTICLES | Sahajanand Medical Technologies Limited (IN) | 2026-04-15 | — | — | EP | claimed |
| US-20020044967-A1 | Sustained release preparations | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-18 | — | — | US | claimed |
| EP-0786986-B1 | Use of an unsaturated fatty alcohol | NOVARTIS AG (CH) | 2002-03-20 | — | — | EP | claimed |
| US-6352998-B2 | A TOPICAL COMPOSITION OF A COMPOUND OF THE FK506 CLASS IN AN ALKANEDIOL, ETHER DIOL, OR DIETHER ALCOHOL SOLVENT, AN UNSATURATED FATTY ALCOHOL AND WATER USED AS AN ANTIINFLAMMATORY AND ANTIHYPERPROLIFERATIVE FOR SKIN DISEASES | NOVARTIS AG (CH) | 2002-03-05 | — | — | US | claimed |
| EP-1147766-A2 | Pharmaceutical compositions | Novartis AG (CH) | 2001-10-24 | — | — | EP | claimed |
| US-20010031769-A1 | Pharmaceutical compositions | MEDA PHARMA SARL (LU) | 2001-10-18 | — | — | US | claimed |
| EP-1126845-A2 | NEW USE OF IMMUNOSUPPRESSANTS FOR MMP-MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-29 | — | — | EP | claimed |
| EP-1064942-A1 | SUSTAINED RELEASE PREPARATIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-03 | — | — | EP | claimed |
| WO-2000015208-A2 | NEW USE OF IMMUNOSUPRESSANTS FOR MMP-MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-23 | — | — | WO | claimed |
| EP-0786986-A1 | PHARMACEUTICAL COMPOSITIONS | Novartis AG (CH) | 1997-08-06 | — | — | EP | claimed |
| WO-1996013249-A1 | PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 1996-05-09 | — | — | WO | claimed |